At Citeline (a Norstella company), we are a global leader in clinical trial intelligence, data, and insights for the life sciences and pharmaceutical industries. We help organizations accelerate drug development, enhance transparency, and improve clinical outcomes through real‑time, decision‑ready intelligence across the entire drug lifecycle. Our solutions provide one of the most comprehensive and continuously updated views of global clinical trials, investigators, sites, pipelines, regulatory requirements, and competitive landscapes—enhanced with AI, curated datasets, and expert analysis. This empowers pharma, biotech, and CRO partners to plan smarter, recruit faster, maintain compliance, and reduce development risk. Our core offerings include: • Clinical Trial Intelligence: Real‑time global data on trials, investigators, and sites. • Drug Development Intelligence: Pipeline insights, market assessments & competitive analysis. • Regulatory & Compliance Intelligence: Tools to support disclosure compliance, mitigate risk & streamline submission workflows. • Competitive Intelligence: Industry and therapeutic‑area insights to stay ahead of evolving markets. Powered by machine learning, real‑world data, and expert‑led research, Citeline delivers reliable, actionable intelligence used by global pharmaceutical companies, CROs, and life sciences innovators. As part of Norstella, we work together to accelerate the connection of treatments to patients around the world.
External link for Citeline
New York, New York, US
London, City of London, GB
Citeline reposted this
Norstella will be at American Society of Clinical Oncology (ASCO) next week! Meet with colleagues from Citeline, MMIT, and Panalgo at Booth 16151 to hear how, together, we're connecting oncology innovation from pipeline to patient. #ASCO26
Everyone has an AI pilot. But only a few harness AI to transform trial execution. This ebook dives into the undeniable, tangible impact AI is making across clinical trial workflows—beyond mere hype. Downlaod the ebook today: https://vist.ly/5563n
China is closing the gap on Western countries in terms of pharma R&D, and in some cases has even moved ahead on developing new therapies. A column in Bloomberg (subscription required) on China’s growing pharma dominance featured data from Citeline’s Pharma R&D Annual Review 2026 Supplement: New Active Substances Launched During 2025. It notes that in 2025, for the first time, China launched more novel medicines than any other country. https://vist.ly/553ax
Season 2 of #SmallBiotechsBigDecisions is just getting started and we couldn't be more excited about the conversations ahead. From board governance and ROI discipline, to clinical trial execution, operational strategy, and the state of the industry — four episodes that go straight to the heart of what biotech leaders are navigating today. This season, Claire Riches, VP of Clinical Solutions at Citeline, is joined by some incredible guests who are shaping the future of biotech: Ross Pettit, Carrie Melvin, Marissa V., and Jennifer Burg. New episodes are dropping soon. Follow us so you don't miss a thing. https://vist.ly/54zrz
We’ll be at ASCO this month! Where? Look for us at booth 16151 — it’s the booth of our parent company, Norstella. Want to pinpoint eligible patients? Book a slot now at ASCO for a demo of Citeline PatientMatch. https://vist.ly/54uxv #ASCO26 | American Society of Clinical Oncology (ASCO)
Today, on International Clinical Trials Day, we recognize the studies, sponsors, and patients driving progress across global drug development. Each completed trial represents a signal of where innovation is heading next. In our upcoming Annual Completed Clinical Trials Report 2026, we’ve analyzed how the clinical landscape is evolving: As this sneak peek shows, oncology continues to dominate early-phase activity (85% Phase I–II), while late-stage trials are gaining momentum in both oncology and metabolic/endocrinology—with the latter seeing a 15% increase, largely driven by the rise of GLP‑1 studies. We’ll be sharing the full analysis soon, watch this space!
FDA expectations for rare disease approvals are evolving...fast. From new evidence frameworks to shifting review outcomes, sponsors are facing increased complexity and uncertainty in how therapies are assessed. So how do you stay ahead—and improve your chances of approval? Join our upcoming webinar on June 11 to explore how to: ✔️Strengthen your evidence strategy across limited patient populations ✔️Navigate regulatory uncertainty with greater confidence ✔️Reduce approval risk for rare and ultra-rare genetic therapies Registration link in the comments.
Pharma R&D Review Findings: While the overall field tightens, the clinical beds keep greening. The phase-by-phase growth rings tell a clear story: Phase I and Phase II have risen steadily for years — and Phase III is fertile again after a mid-period plateau. That matters, because more late-stage buds today can mean more therapies flowering into approvals tomorrow. Ready to follow the growth cycle in full? Get the full analysis. (Link in the comments!)
Visit our team at ScopeX!
Greetings from a very sunny Seaport in Boston for the inaugural ScopeX Conference! This is the first conference from the producers of SCOPE 365, with a focus on everyone’s favourite topics: Data Strategies and AI Innovation in Clinical Research. It’s fantastic to be able to reconnect with colleagues and clients at such an intimate conference. Message me for a catch up if you’re in the area! Citeline dream team activated Rob Rutz Larissa Jacobson (Rayher) Lauren Lovelace Andrew Cardona #SCOPEsummit
📍 We are live from #SCOPEX in Boston! AI in clinical research is no longer the differentiator: outcomes are. A standout session from Claire Riches (Citeline) and Ross Pettit (Kestrel Therapeutics) focused on how to turn data into decision-ready intelligence and ultimately, more predictable trial outcomes. The TL;DR: It’s not just about having data or AI, it’s about embedding trusted, connected intelligence directly into workflows. This is where clinical intelligence makes the difference: helping teams move beyond analysis to real, repeatable outcomes. If you’re at SCOPEX, come connect with the Citeline team to learn more!